Back

Landmark Medicines plans human study for nasal GLP-1 platform

Verifying
  • Landmark Medicines announced plans to advance its nasal drug-delivery platform toward a human volunteer study.
  • Semaglutide is among the GLP-1 molecules being evaluated before final selection.
  • Landmark will attend BIO-Europe 2026 in Cologne from Nov. 9-11.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.